案例研究：在新西兰和澳大利亚完成两剂皮下接种改良安卡拉痘苗（MVA-BN）疫苗后出现的猴痘突破性感染。
Case study: breakthrough mpox infection in Aotearoa New Zealand and Australia after completed two-dose course of subcutaneous modified vaccinia Ankara (MVA-BN) vaccines.
作者信息
Cornelisse Vincent J, Kearley John J M, Vargas Castillo Jose, Macharg Lindsay, McLaughlin Virginia A, Jack Susan J, Swift Caitlin
机构信息
<institution content-type="university">Kirketon Road Centre, NSW Health</institution>, <city>Sydney</city>, <state>NSW</state>, <country>Australia</country>; and <institution content-type="university">The Kirby Institute, University of NSW</institution>, <city>Sydney</city>, <state>NSW</state>, <country>Australia</country>; and <institution content-type="university">Monash University</institution>, <city>Melbourne</city>, <state>Vic.</state>, <country>Australia</country>.
<institution content-type="university">Kirketon Road Centre, NSW Health</institution>, <city>Sydney</city>, <state>NSW</state>, <country>Australia</country>.
出版信息
Sex Health. 2023 Dec;20(6):585-587. doi: 10.1071/SH23139.
BACKGROUND
In August 2022, in response to a global mpox outbreak, the World Health Organization recommended the Vaccinia vaccination for at-risk people.
METHODS
Case study.
RESULTS
We describe a case of a HIV-negative bisexual man who developed a symptomatic mpox infection 13weeks after completing a two-dose course of subcutaneous third-generation modified vaccinia Ankara vaccines. The case likely acquired his mpox infection in the USA; was diagnosed in Aotearoa, New Zealand; and was followed-up in Australia, as he was actively travelling during his infection.
CONCLUSIONS
This case highlights the importance of maintaining clinical suspicion for mpox in people who present with consistent symptoms, even if they are fully vaccinated. Also, as he travelled around Aotearoa, New Zealand, and Australia during his infection, this case highlights how public health authorities and clinicians can cooperate across jurisdictional boundaries to support cases and minimise the risk of onward transmission.
背景
2022年8月，为应对全球猴痘疫情，世界卫生组织建议为高危人群接种牛痘疫苗。
方法
病例研究。
结果
我们描述了一例HIV阴性双性恋男性病例，该患者在完成两剂皮下注射第三代改良安卡拉痘苗疫苗疗程13周后出现有症状的猴痘感染。该病例可能在美国感染猴痘；在新西兰奥特亚罗瓦被诊断；在澳大利亚接受随访，因为他在感染期间一直在积极旅行。
结论
该病例强调了对出现持续症状的人群保持猴痘临床怀疑的重要性，即使他们已完全接种疫苗。此外，由于他在感染期间在新西兰奥特亚罗瓦和澳大利亚各地旅行，该病例凸显了公共卫生当局和临床医生如何跨管辖边界合作以支持病例并将进一步传播的风险降至最低。
Zotero 插件